NRXP
NRX Pharmaceuticals Inc
3.00$
-4.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | +0.0% | -100.0% | – | – | +0.0% | -100.0% | – | +306.2% | +8.6% | +3.1% | – | |
| – | -50.0% | +0.0% | +0.0% | +100.0% | -50.0% | +100.0% | -100.0% | – | +268.1% | +56.7% | +5.9% | – | |
| – | – | – | – | – | – | – | -100.0% | – | +356.7% | -42.7% | -5.1% | – | |
| – | -23.5% | -31.0% | +60.4% | -78.2% | +69.6% | -22.4% | +22.8% | +44.8% | -61.0% | +134.6% | +61.7% | – | |
| – | -24.9% | +127.0% | -0.1% | -43.2% | +7.8% | +13.3% | -6.8% | +2.4% | +62.7% | -16.5% | +24.4% | – | |
| – | -24.1% | +36.1% | +17.5% | -57.2% | +20.3% | +5.9% | -3.0% | +13.2% | +20.1% | -1.0% | +34.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +100.0% | +187.5% | +269.1% | -100.0% | – | – | – | – | – | -65.3% | +3.0% | – | |
| – | – | – | – | – | – | – | – | – | – | -497.2% | – | – | |
| – | -3,585.0% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -497.2% | – | – | |
| – | – | – | – | – | – | – | – | – | – | -191.2% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.